The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here, here) to the world of biotech, so thought it was worth reflecting on the prevailing venture formation landscape and offering up some counterpoints.
New therapeutic platforms, like those based on cell and gene therapy, provide potential to address diseases in new ways and hold tremendous promise for alleviating human suffering. Despite this, progress often reaches a critical juncture when attempts are made to scale manufacturing from research to late-stage clinical trials and commercialization.
This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Some of the most promising and innovative research underlying biotech start-ups arises in research institutions. It is often with those very institutions that we can best collaborate to advance such innovations. Academic researchers are insightful scientific advisors in new areas of biology and are poised to assist in important, thoughtful breakthroughs in ways that contract research organization (CRO) researchers sometimes are not.
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.
Disarm Therapeutics has a full-time CEO—the neuro-focused biotech has signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant until February this year.
The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.